Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Nirmatrelvir-ritonavir for COVID-19

by Lee, Todd C , McDonald, Emily G

in Administration, Oral / Antiretroviral drugs / Antiviral agents / Antiviral drugs / Complications and side effects / Coronaviruses / COVID-19 / COVID-19 Drug Treatment / COVID-19 vaccines / Cytochrome P-450 CYP3A Inhibitors - therapeutic use / Disease progression / Drug Combinations / Drug dosages / Drug Interactions / Drug therapy, Combination / Humans / Inhibitor drugs / Internal Medicine / Lactams - therapeutic use / Leucine - therapeutic use / Nitriles - therapeutic use / Practice / Proline - therapeutic use / Ritonavir - therapeutic use / SARS-CoV-2 / Severe acute respiratory syndrome coronavirus 2 / Viral Protease Inhibitors - therapeutic use

2022

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Nirmatrelvir-ritonavir for COVID-19

by Lee, Todd C , McDonald, Emily G

2022

Confirm

Do you wish to request the book?

Nirmatrelvir-ritonavir for COVID-19

by Lee, Todd C , McDonald, Emily G

2022

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Nirmatrelvir-ritonavir for COVID-19

Lee, Todd C,

McDonald, Emily G

2022

Overview

McDonald and Lee present several facts about nirmatrelvir-ritonavir. Ritonavir-boosted nirmatrelvir is a Health Canada-approved oral antiviral medication with activity against SARS-CoV-2 Treatment is indicated for adult (≥ 18 yr) outpatients with nonhypoxic COVID-19 who are at high risk of severe disease progression.

Share this book

Add to My Shelf

Publisher

Elsevier Inc,CMA Impact Inc,CMA Joule Inc,CMA Impact, Inc

Subject

Administration, Oral

/ Antiretroviral drugs

/ Antiviral agents

/ Antiviral drugs

/ Complications and side effects

/ Coronaviruses

/ COVID-19